SHANGHAI, April 27, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it filed its annual report on Form 20-F for the year ended December 31, 2010 with the Securities and Exchange Commission. The annual report can be accessed on WuXi PharmaTech's website at http://www.wuxiapptec.com under the Investor Relations section. WuXi PharmaTech will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to its shareholders and ADS holders upon request. Requests should be directed to Ronald Aldridge, Director of Investor Relations, by email at ir@wuxiapptec.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO)
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .
|
For more information, please contact: |
|
|
WuXi PharmaTech (Cayman) Inc. |
|
|
Ronald Aldridge (for investors) |
|
|
Director of Investor Relations |
|
|
Tel: +1-201-585-2048 |
|
|
Email: ir@wuxiapptec.com |
|
|
Stephanie Liu (for the media) |
|
|
Tel: +86-21-5046-4362 |
|
|
Email: pr@wuxiapptec.com |
|
![[Poster] Analytical Performance Experimentation assessment of the miLab™ MAL Malaria system for the detection of Plasmodium falciparum in clinical samples in Lagos, Nigeria](https://mma.prnasia.com/media2/2395917/Poster__Analytical_Performance_Experimentation_assessment_of_the_miLab__MAL_Malaria_system_for_the_d.jpg?p=medium600)